BioSpace News Archive

Business

ESSA Pharma Inc. Reports Results of Annual General and Special Meeting of Shareholders

ESSA Pharma Inc. is pleased to announce the results of the votes on matters considered at its Annual General and Special Meeting of Shareholders held on March 28, 2018 in Vancouver, British Columbia, Canada.

March 28, 2018
·
8 min read
Toshiba Heavy-Ion Therapy System Awarded by Yonsei University Health System

Toshiba Energy Systems & Solutions Corporation in collaboration as a consortium with DK Medical Solutions is awarded a contract to supply a heavy-ion therapy system to Yonsei University Health System (YUHS), one of the leading providers of medical services in Korea.

March 28, 2018
·
3 min read
Biotech Bay

Five Deaths in Genentech’s Hemlibra Patients

The Hemophilia Federation of America and the National Hemophilia Foundation announced that they had been contacted by Genentech, a Roche company, about the deaths of five patients receiving Hemlibra (emicizumab-kxwh) for hemophilia A.

March 28, 2018
·
2 min read
·
Mark Terry
Biotech Bay

Tempest Therapeutics Leaps into IDO Development with $70M

Versant Ventures spinoff company Tempest Therapeutics secured $70 million in a Series B funding to advance the company’s immunotherapy pipeline.

March 28, 2018
·
2 min read
·
Alex Keown
Deals

The Big Tease: Takeda Considers Buying Shire

Shire stock prices jumped up to 26 percent on rumors that Takeda Pharmaceuticals was considering a buyout.

March 28, 2018
·
3 min read
·
Mark Terry
Drug Development

Accelerating the Start of Clinical Trials

In STAT News, Mary Jo Lamberti, a research fellow at the Tufts Center for the Study of Drug Development, unveiled an analysis of the amount of time it takes to initiate a clinical trial.

March 28, 2018
·
2 min read
·
Alex Keown
Business

Homology Medicines Snags $144 Million IPO

Homology Medicines has raised $144 million in an initial public offering of stock.

March 28, 2018
·
2 min read
·
Alex Keown
FDA

FDA Gives Mylan’s New HIV Drug a Thumbs-Up

The U.S. Food and Drug Administration (FDA) approved Mylan NV’s Symfi (efavirnenz, lamivudine and tenofovir disoproxil fumarate) for adult and pediatric HIV-1 patients.This marks the third HIV approval for the company.

March 28, 2018
·
2 min read
·
Mark Terry
Deals

With Cash in Hand, Novartis Could Seek Deal to Bolster Drug Pipeline

Following an agreement to sell its share of a consumer health business unit to GlaxoSmithKline for $13 billion new Novartis Chief Executive Officer Vasant Narasimhan has some excess cash to use to shape the company in the coming years.

March 28, 2018
·
2 min read
·
Alex Keown
Business

Celgene and bluebird bio Team Up in New Deal

Celgene and bluebird bio have inked a development and promotion deal for bb2121, bluebird’s B-cell maturation antigen (BCMA) CAR-T therapy for relapsed/refractory multiple myeloma (rrMM).

March 28, 2018
·
2 min read
·
Mark Terry